The study analyzed that the post-operative pain
therapeutics pipeline comprises approximately 39 drug candidates in different stages of
development. Post-operative pain is one of the most common problem experienced
by a person after any surgery. The intensity of pain can vary from acute to
chronic depending upon the time it lasts. It starts when pain receptors
activate an electrical signal that travels to the spinal cord. The spinal cord
then transmits the signal to the brain. It involves the interaction of various
chemicals, known as neurotransmitters, in the body, which together act to
produce the sensation of pain in a person.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis
Innocoll Holdings plc is using CollaRx technology platform for the
development of INL-001 for the treatment of post-operative pain. The CollaRx
technology platform produces a lyophilized porous matrix of purified collagen
that can be implanted at the time of surgery or applied topically to chronic or
acute traumatic wounds. The CollaRx matrices are biodegradable and
bio-resorbable. The in vivo release of drugs incorporated into the CollaRx
matrix takes place via a combination of dissolution, diffusion and the
interactive characteristics of the active drug and the formulation that can be
modified to affect controlled release.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for
post-operative pain include DURECT Corporation, Elite Pharmaceuticals, Inc.,
Cara Therapeutics, Inc. and others.
No comments:
Post a Comment